Journal article icon

Journal article

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

Abstract:

Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h. Methods: To capture both possible outcomes of OXi4503 treatment on cell death, plasma samples for analysis by M30 and M65 ELISAs, which measure different circulating forms of cytokeratin 18 as biomarker...

Expand abstract

Actions


Access Document


Publisher copy:
10.1038/bjc.2012.165

Authors


Expand authors...
Journal:
British Journal of Cancer
Volume:
106
Issue:
11
Pages:
1766-1771
Publication date:
2012-05-22
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
Source identifiers:
335181
Language:
English
Keywords:
Pubs id:
pubs:335181
UUID:
uuid:1243d56e-d10c-4a31-bd38-5f0ad1410a4b
Local pid:
pubs:335181
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP